Carvedilol
- Generic Name
- Carvedilol
- Brand Names
- Coreg
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N2O4
- CAS Number
- 72956-09-3
- Unique Ingredient Identifier
- 0K47UL67F2
- Background
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs ...
- Indication
Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.
- Associated Conditions
- Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
- Associated Therapies
- -
Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Bispebjerg Hospital
- Target Recruit Count
- 2760
- Registration Number
- NCT03778554
- Locations
- 🇩🇰
Bispebjerg Hospital, Dept. of Cardiology Y builing 67, 1.floor, Bispebjerg Bakke 23, Copenhagen, Denmark
Beta-blockers for Oesophageal Varices
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2019-10-03
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 1200
- Registration Number
- NCT03776955
- Locations
- 🇬🇧
Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Royal London Hospital (Barts), London, United Kingdom
🇬🇧King's College Hosptial NHS Foundation Trust (Denmark Hill), London, United Kingdom
Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)
- Conditions
- Interventions
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- Michele Tagliati, MD
- Target Recruit Count
- 15
- Registration Number
- NCT03775096
- Locations
- 🇺🇸
Michele L Lima Gregorio, Los Angeles, California, United States
Carvedilol for Prevention of Esophageal Varices Progression
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT03736265
- Locations
- 🇨🇳
Beijing Ditan Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Shanghai Jiao Tong University, Shanghai, Shanghai, China
🇨🇳Beijing Friendship Hospital, Beijing, Beijing, China
Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Universidade Federal do Rio de Janeiro
- Target Recruit Count
- 80
- Registration Number
- NCT03720067
- Locations
- 🇧🇷
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract
- Conditions
- Interventions
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Keimyung University Dongsan Medical Center
- Target Recruit Count
- 104
- Registration Number
- NCT03587558
- Locations
- 🇰🇷
Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷Seoul Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Severance Cardiovascular Hospital, Seoul, Korea, Republic of
Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country.
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2018-05-31
- Lead Sponsor
- Makerere University
- Target Recruit Count
- 50
- Registration Number
- NCT03542058
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 817
- Registration Number
- NCT03418961
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States
🇺🇸Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States
Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD
- Conditions
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- VA Greater Los Angeles Healthcare System
- Target Recruit Count
- 21
- Registration Number
- NCT03370835
- Locations
- 🇺🇸
VA West Los Angeles Medical Center, Los Angeles, California, United States
WFA+M2BP in Evaluation of Portal Hypertension and Clinical Outcome in Patients With Liver Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03195634
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.